Aller au contenu principal
Institution scientifique

Argos Therapeutics (United States)

Durham · US · company

148Publications signalées
9384Citations signalées
12Thèmes principaux

Principaux domaines

Immunotherapy and Immune ResponsesMaritime and Coastal ArchaeologyHIV Research and TreatmentCAR-T cell therapy researchCancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyRNA Interference and Gene DeliveryImmune Cell Function and InteractionCancer Genomics and DiagnosticsLymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies ResearchAncient and Medieval Archaeology Studies

Évolution annuelle

20001
20012
20023
20041
20054
20062
20075
20087
20097
20109
20126
20136
20142
20151
20163
20174
20184
20193
20203
20213
20224
20234
20245
202511
20266

Publications récentes

Accès ouvert 2025 conference-abstractOpenAlex

TIP-27. An assessment of the Tumor Monorail Device (TMD) for repeated sampling as part of a trial evaluating the combination of D2C7-IT and an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery (CED) and cervical perilymphatic injections (CPLIs) of 2141-V11 in recurrent glioblastoma (rGBM) patients

Annick Desjardins, Vidya Chandramohan, Nassir Mokarram, S. Meehan et autres

0 citationsNeuro-Oncology

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.